

FORM 144

OMB APPROVAL	
OMB Number: 3235-0101	
Expires: June 30, 2020	
Estimated average burden hours per response..... 1.00	
SEC USE ONLY	
DOCUMENT SEQUENCE NO.	
CUSIP NUMBER	
00653A107	
WORK LOCATION	
(e) TELEPHONE NO.	
AREA CODE	NUMBER
+44	1235 430000
STATE ZIP CODE	
Oxfordshire OX14 4RX	

1 (a) NAME OF ISSUER (Please type or print)		(b) IRS IDENT. NO.	(c) S.E.C. FILE NO.	WORK LOCATION	
ADAPTIMMUNE THERAPEUTICS PLC		N/A	001-37368		
1 (d) ADDRESS OF ISSUER		STREET		CITY	STATE ZIP CODE
60 Jubilee Avenue, Milton Park,		Abingdon,		Oxfordshire	OX14 4RX
				(e) TELEPHONE NO.	
				AREA CODE	NUMBER
				+44	1235 430000
2 (a) NAME OF PERSON FOR WHOSE ACCOUNT THE SECURITIES ARE TO BE SOLD		(b)	RELATIONSHIP TO ISSUER	(c) ADDRESS STREET	CITY STATE ZIP CODE
Helen Tayton-Martin			CBO	c/o 60 Jubilee Avenue, Milton Park,	Abingdon, Oxfordshire OX14 4RX

3 (a) Title of the Class of Securities To Be Sold	(b) Name and Address of Each Broker Through Whom the Securities are to be Offered or Each Market Maker who is Acquiring the Securities	SEC USE ONLY	(c) Number of Shares or Other Units To Be Sold (See instr. 3(c))	(d) Aggregate Market Value (See instr. 3(d))	(e) Number of Shares or Other Units Outstanding (See instr. 3(e))	(f) Approximate Date of Sale (See instr. 3(f)) (MO. DAY YR.)	(g) Name of Each Securities Exchange (See instr. 3(g))
		Broker-Dealer File Number					
ADS	MAXIM GROUP 405 LEXINGTON AVENUE NY, NY 10174		200,000	\$1.75 MILL	\$153 MILL	8/3/2020	Nasdaq
ADS	MAXIM GROUP 405 LEXINGTON AVENUE NY, NY 10174		291,000	\$2.69 MILL	\$153 MILL	9/3/2020	Nasdaq

SEC 1147 (08-07)

TABLE I — SECURITIES TO BE SOLD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired (If gift, also give date donor acquired)	Amount of Securities Acquired	Date of Payment	Nature of Payment
ADS			ADAPTIMMUNE THERAPEUTICS, PLC	200,000	N/A	N/A

INSTRUCTIONS: If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

TABLE II — SECURITIES SOLD DURING THE PAST 3 MONTHS

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds

REMARKS:

This proposed sale is made pursuant to a plan intended to comply with Rule 10b5-1(c), previously entered into on June 28, 2019, at which time I was not aware of material nonpublic information

INSTRUCTIONS:

See the definition of “person” in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (c) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

ATTENTION: *The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.*

8/3/20

DATE OF NOTICE
June 28, 2019

DATE OF PLAN ADOPTION OR GIVING OF INSTRUCTION,

IF RELYING ON RULE 10B5-1



(SIGNATURE)

The notice shall be signed by the person for whose account the securities are to be sold. At least one copy

of the notice shall be manually signed Any copies not manually signed shall bear typed or printed signatures.

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)